Rationale and Design of the FAIR-HF2-DZHK05 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Open Access
- 28 January 2025
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 27 (4) , 681-689
Abstract
Aims: While it is widely accepted that intravenous (IV) iron improves functional capacity, symptoms, and cardiovascular outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF) diagnosed with iron deficiency (ID), three recently published cardiovascular outcome trials (AFFIRM-AHF, IRONMAN and HEART-FID) of IV iron supplementation in HF failed to demonstrate a significant benefit on their respective primary endpoints. Dosing of IV iron after the initial correction of baseline ID – by design or as a result of trial circumstances – was relatively low (i.e. 1000 mg/year). The second objective of the study is to create prospective evidence for patients fulfilling the new definition of ID for patients with HF, i.e. for those with a transferrin saturation 800 ng/ml are met on repeat visits. The trial will evaluate three primary hypotheses: (i) time to first event of cardiovascular death or hospitalization for HF, (ii) the rate of total (first and recurrent) HF hospitalizations (both analysed in the full study population), and (iii) the time to first event of cardiovascular death or hospitalization for HF in patients with a transferrin saturation <20% at baseline. The familywise type I error rate across the three primary endpoint hypotheses will be controlled using the Hochberg procedure (alpha 0.05). Conclusion: The FAIR-HF2 will evaluate the efficacy of FCM in patients with HFrEF in improving cardiovascular outcomes by utilizing a more aggressive approach towards iron supplementation ensuring prevention of transitional ID after initial repletion targets have been met.Keywords
Funding Information
- German Centre for Cardiovascular Research
- German Heart Foundation
- Else Kroener-Fresenius-Stiftung
This publication has 38 references indexed in Scilit:
- Intravenous Iron and SGLT2 Inhibitors in Iron-Deficient Patients with Heart Failure and Reduced Ejection FractionESC Heart Failure, 2024
- Iron Deficiency in Heart Failure: A Scientific Statement from the Heart Failure Society of AmericaJournal of Cardiac Failure, 2023
- Dosing of Iron Supplementation for Iron-Deficient Patients with Heart Failure: Should we Prefer More Intensive or Less Intensive Repletion Targets?European Journal of Heart Failure, 2023
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Journal of Heart Failure, 2022
- Criteria for Iron Deficiency in Patients With Heart FailureJACC, 2022
- Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular EventsJAMA Cardiology, 2019
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsJACC, 2018
- Iron Deficiency Impairs Contractility of Human Cardiomyocytes Through Decreased Mitochondrial FunctionEuropean Journal of Heart Failure, 2018
- Effects of Ferric Carboxymaltose on Hospitalisations and Mortality Rates in Iron-Deficient Heart Failure Patients: An Individual Patient data Meta-AnalysisEuropean Journal of Heart Failure, 2017
- Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: Data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trialAmerican Heart Journal, 2007